21 completed. 21 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 21 |
| Phase 2 | 1 | Completed 1 |
Follow Panuveitis: new trials by email Literature Review of Panuveitis trials Research Report on Panuveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Yutiq 0.18 MG Drug Implant, Sham Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Texas Retina Associates | 10 | 2022-10-05 | 2026-10-05 |
| Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Infliximab, Cyclophosphamide - Behcet's Disease, Vasculitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 53 | 2018-05-25 | 2023-07-03 |
| Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis | Phase 3 | Completed | Peking Union Medical College Hospital | 28 | 2017-06-30 | 2021-02-23 |
| Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis 4 mg CLS-TA Suprachoriodal Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Clearside Biomedical, Inc. | 38 | 2017-04-04 | 2021-06-23 |
| Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%) - Anterior Uveitis | Phase 3 | Completed | Eyegate Pharmaceuticals, Inc. | 251 | 2016-01-16 | 2018-07-26 |
| Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis 4mg CLS-TA Suprachoriodal Injection, Sham Procedure - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Clearside Biomedical, Inc. | 160 | 2015-11-17 | 2021-05-28 |
| A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease Infliximab - Behcet Disease | Phase 3 | Completed | Janssen Korea, Ltd., Korea | 33 | 2015-07-22 | 2019-10-17 |
| Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis Sham Injection, FAI Insert - Posterior Uveitis, Intermediate Uveitis | Phase 3 | Completed | EyePoint Pharmaceuticals, Inc. | 153 | 2015-06-02 | 2020-07-21 |
| A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease Apremilast, Placebo - Behçet's Syndrome | Phase 3 | Completed | Amgen | 207 | 2014-12-30 | 2021-07-22 |
| Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions TA-650 - Behcet's Disease, Behcet Syndrome | Phase 3 | Completed | Tanabe Pharma Corporation | 18 | 2012-01-01 | 2026-01-07 |
| Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution - Anterior Uveitis | Phase 3 | Completed | Eyegate Pharmaceuticals, Inc. | 193 | 2011-12-01 | 2013-03-29 |
| Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis Trimethoprim-Sulfamethoxazole - Ocular Toxoplasmosis | Phase 3 | Completed | University of Campinas, Brazil | 141 | 2011-10-01 | 2016-07-12 |
| A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis adalimumab - Uveitis | Phase 3 | Completed | AbbVie | 424 | 2010-11-23 | 2021-07-12 |
| Phase III Study in Refractory Behcet's Disease AIN457, Placebo - Behcet Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 118 | 2009-10-01 | 2015-08-31 |
| A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Placebo, LX211 - Uveitis, Posterior, Uveitis, Intermediate | Phase 3 | Completed | Lux Biosciences, Inc. | 218 | 2007-01-01 | 2012-10-11 |
| A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Placebo, LX211 - Uveitis, Posterior, Uveitis, Intermediate | Phase 3 | Completed | Lux Biosciences, Inc. | 232 | 2007-01-01 | 2012-06-22 |
| A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Placebo, LX211 - Uveitis, Anterior, Panuveitis | Phase 3 | Completed | Lux Biosciences, Inc. | 108 | 2007-01-01 | 2012-06-22 |
| A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Dexamethasone, dexamethasone, Sham injection - Intermediate Uveitis, Posterior Uveitis | Phase 2 / Phase 3 | Completed | Allergan | 229 | 2006-05-01 | 2011-04-14 |
| Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) Cyclosporin A, Interferon-alpha2a - Behcet's Disease, Panuveitis | Phase 3 | Completed | University Hospital Tuebingen | 37 | 2004-11-01 | 2018-05-17 |
| Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Difluprednate Ophthalmic Emulsion - Anterior Uveitis, Panuveitis | Phase 3 | Completed | Sirion Therapeutics, Inc. | 140 | 2002-08-01 | 2006-12-04 |
Showing 20 of 21. Sign in to see all of them.
Uveitis (10) · Uveitis, Posterior (10) · Uveitis, Intermediate (9) · Behcet Syndrome (7) · Uveitis, Anterior (7) · Chorioretinitis (1) · Inflammation (1) · Retinal Vasculitis (1) · Toxoplasmosis, Ocular (1) · Vasculitis (1)
Eye Diseases (21) · Uveal Diseases (21) · Uveitis (11) · Cardiovascular Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hereditary Autoinflammatory Diseases (7) · Mouth Diseases (7) · Skin Diseases (7) · Skin Diseases, Genetic (7) · Skin Diseases, Vascular (7) · Skin and Connective Tissue Diseases (7) · Stomatognathic Diseases (7) · Uveitis, Anterior (7)
salicylhydroxamic acid (3) · Cyclosporine (2) · Fluocinolone Acetonide (2) · Infliximab (2) · Interferon alpha-2 (2) · Triamcinolone Acetonide (2) · Adalimumab (1) · Benzalkonium Compounds (1) · Cyclophosphamide (1) · Dexamethasone (1) · Drug Implants (1) · Ophthalmic Solutions (1) · Sodium Chloride (1) · Sulfamethoxazole (1) · Trimethoprim (1)
Lux Biosciences, Inc. (3) · Clearside Biomedical, Inc. (2) · Eyegate Pharmaceuticals, Inc. (2) · Sirion Therapeutics, Inc. (2) · AbbVie (1) · Allergan (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · EyePoint Pharmaceuticals, Inc. (1) · Janssen Korea, Ltd., Korea (1) · Novartis Pharmaceuticals (1) · Peking Union Medical College Hospital (1) · Tanabe Pharma Corporation (1) · Texas Retina Associates (1) · University Hospital Tuebingen (1)
United States (11) · France (7) · Germany (7) · India (7) · Austria (4) · Canada (4) · Israel (4) · South Korea (4) · United Kingdom (4) · Greece (3) · Brazil (2) · Italy (2) · Japan (2) · Spain (2) · Switzerland (2)
Eddy Anglade, M.D. (3) · John D. Sheppard, M.D. (2) · Flavio Leonin Jr., MD (1) · Ina Koetter, MD (1) · Kazuoki Kondo, MD (1) · Rodrigo PC Lira, PhD (1) · Shigeaki Ohno, PhD (1) · Shunsei Hirohata, MD (1) · Thomas Ciulla, MD (1)
PMID 36399237, PMID 36787524, PMID 12095806, PMID 21220619, PMID 23290985, PMID 23411886, PMID 23761087, PMID 27310969, PMID 31722152, PMID 33157077, PMID 34322164, PMID 34741564, PMID 35798511, PMID 36055922, PMID 36578194, PMID 37316690, PMID 38027419
2009 (2), 2014 (1)